Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest

• Autors principals: Alexander Egeberg (Autor), Denis Jullien (Autor), Kristian Gaarn Du Jardin (Autor), Diamant Thaçi (Autor)
• Format: Llibre
• Publicat: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Background Five-year tildrakizumab safety data have been reported as exposure-adjusted incidence rates (EAIRs) of patients with events per 100 patient-years (PYs) of exposure. Objectives To present 5-year safety data from reSURFACE 1/2 phase 3 trials as EAIRs of events per 100 PYs of exposure, and t...